Hls Therapeutics (TSE:HLS) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
HLS Therapeutics Inc. has announced findings from the REDUCE-IT clinical trial, revealing that their drug VASCEPA significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with high or low Lipoprotein(a) levels. The analysis, which also featured in the Journal of the American College of Cardiology, shows that VASCEPA offers a consistent treatment benefit across different patient subgroups, regardless of their baseline LDL-C or triglyceride levels.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.